Business Description
Pulmonx Corp
NAICS : 334510
SIC : 3842
ISIN : US7458481014
Share Class Description:
STU:4NI: Ordinary SharesDescription
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.04 | |||||
| Equity-to-Asset | 0.59 | |||||
| Debt-to-Equity | 0.56 | |||||
| Debt-to-EBITDA | -1.08 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -0.71 | |||||
| Beneish M-Score | -3.15 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -17.4 | |||||
| 3-Year EBITDA Growth Rate | 19.3 | |||||
| 3-Year EPS without NRI Growth Rate | 20.3 | |||||
| 3-Year FCF Growth Rate | 31.1 | |||||
| 3-Year Book Growth Rate | -21.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 5.11 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 19.67 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 80.4 | |||||
| 9-Day RSI | 71.09 | |||||
| 14-Day RSI | 65.25 | |||||
| 6-1 Month Momentum % | -36.2 | |||||
| 12-1 Month Momentum % | -44.39 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.97 | |||||
| Quick Ratio | 7.92 | |||||
| Cash Ratio | 7.03 | |||||
| Days Inventory | 305.45 | |||||
| Days Sales Outstanding | 50.27 | |||||
| Days Payable | 49.37 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.6 | |||||
| Shareholder Yield % | -3.65 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 74.19 | |||||
| Operating Margin % | -77.37 | |||||
| Net Margin % | -75.56 | |||||
| FCF Margin % | -47.31 | |||||
| ROE % | -49.06 | |||||
| ROA % | -32.39 | |||||
| ROIC % | -124.97 | |||||
| 3-Year ROIIC % | -113.43 | |||||
| ROC (Joel Greenblatt) % | -212.88 | |||||
| ROCE % | -33.89 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3.9 | |||||
| PB Ratio | 3 | |||||
| Price-to-Tangible-Book | 3.22 | |||||
| EV-to-EBIT | -4.9 | |||||
| EV-to-EBITDA | -5.04 | |||||
| EV-to-Revenue | 3.44 | |||||
| EV-to-Forward-Revenue | 2.76 | |||||
| EV-to-FCF | -6.75 | |||||
| Price-to-Net-Current-Asset-Value | 4.24 | |||||
| Price-to-Net-Cash | 7.37 | |||||
| Earnings Yield (Greenblatt) % | -20.41 | |||||
| FCF Yield % | -11.28 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Pulmonx Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 70.886 | ||
| EPS (TTM) (€) | -1.388 | ||
| Beta | 1.05 | ||
| Volatility % | 50.26 | ||
| 14-Day RSI | 65.25 | ||
| 14-Day ATR (€) | 0.284056 | ||
| 20-Day SMA (€) | 6.375 | ||
| 12-1 Month Momentum % | -44.39 | ||
| 52-Week Range (€) | 5.1 - 13.6 | ||
| Shares Outstanding (Mil) | 39.15 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pulmonx Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pulmonx Corp Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Pulmonx Corp Frequently Asked Questions
What is Pulmonx Corp(STU:4NI)'s stock price today?
The current price of STU:4NI is €7.30. The 52 week high of STU:4NI is €13.60 and 52 week low is €5.10.
When is next earnings date of Pulmonx Corp(STU:4NI)?
The next earnings date of Pulmonx Corp(STU:4NI) is 2024-10-30 Est..
Does Pulmonx Corp(STU:4NI) pay dividends? If so, how much?
Pulmonx Corp(STU:4NI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers